By Matthew Perlman ( June 5, 2023, 8:54 PM EDT) -- The Third Circuit on Monday refused a rehearing bid from Niaspan buyers accusing AbbVie Inc. and Teva Pharmaceuticals Ltd. of scheming to delay a generic version of the cholesterol drug, after an appeals panel found the lower court was right not to certify a class of insurance plans and other end payors....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.